Vector Model and Indexing for Rational Drug Use Clinical

Data Characteristics

Data for rational drug use clinical trial pre-screening comes from drug inserts, clinical guidelines, medical literature, drug interaction databases, and structured/unstructured parts of patient electronic medical records. Update frequencies vary: drug inserts and clinical guidelines typically update quarterly or annually, while medical literature is continuously published. Document structures are complex, ranging from fixed chapter formats in drug inserts to narrative text in clinical guidelines. Fields and units include drug names, dosages (e.g., mg, g), administration routes, indications, contraindications, adverse reactions, drug interactions (e.g., CYP450 enzyme inhibition/induction), patient age (years), weight (kg), and liver/kidney function indicators (e.g., CrCl value ml/min). Units are highly standardized but expressions vary.

Constraints on Vector Models and Indexing

Data characteristics in rational drug use impose specific constraints on vector models and indexing. First, critical information like drug names and dosages requires high-precision matching, tolerating no semantic drift. This demands strong entity recognition and domain-specific vocabulary understanding from the vector model. Second, highly related information, such as drug interactions and contraindications, often appears in different documents or sections of the same document. The vector model must capture complex long-range dependencies, and the index must efficiently recall relevant context. Third, varying data update frequencies require incremental update mechanisms for the index, avoiding resource consumption and delays from full rebuilds. Finally, accurate matching of patient-specific indicators, such as critical liver and kidney function values, challenges numerical data vectorization, requiring special handling to ensure accurate numerical semantics.

Configuration Guidelines

Configuration Item	Recommended Value	Rationale
`Chunk size`	`512 characters`	Ensures completeness of individual drug or interaction descriptions, preventing truncation of key information.
`Overlap Length`	`64 characters`	Maintains contextual continuity, helping the vector model understand cross-paragraph relationships, especially for clinical guidelines.
`Recall count`	`Top 10 entries`	Considers the complexity of drug interactions and multi-factor evaluation, requiring a broader initial recall scope.
`Similarity threshold`	`0.75`	Balances recall and precision, ensuring retrieved results are highly relevant to rational drug use rules and avoiding irrelevant information.
`embeddingModel`	`doubao-embedding-large`	Offers better understanding of complex medical terminology and long texts compared to general-purpose models.
`Multi-Vector Support`	Enabled	Improves retrieval accuracy and semantic understanding for tabular data (e.g., drug dosage tables) or structured fields.

Common Pitfalls

After enabling the doubao-embedding-large model, a 401 Unauthorized error occurs during connection testing. This typically indicates incorrect custom request address or API Key configuration, failing server-side authentication.
Retrieval results contain a large amount of irrelevant or low-relevance drug information. This might be due to a Similarity threshold set too low, leading to an overly broad vector recall range, or an excessively long Chunk size introducing too much noise.
After updating drug inserts, related clinical trial pre-screening results do not reflect the latest information promptly. This might be because the index lacks an incremental update mechanism or the update task did not trigger correctly.

Verification Steps

Retrieve typical drug contraindication cases. Check if the results include critical interaction descriptions and dosage adjustment recommendations, and cross-reference with the latest drug insert.
Use simulated patient data (including specific liver and kidney function indicators) to query applicable drug dosages. Ensure the returned dosage ranges align with clinical guideline recommendations.
After an incremental data update, immediately retrieve affected drug information. Verify if the retrieval results reflect the latest data changes, such as new indications or adverse reactions.

The values provided are common starting points and should be measured against specific samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.